SCHEMBL6445925

SCHEMBL6445925

O=C(Nc1nnc(-c2cc(Cl)cc(Cl)c2O)s1)c1ccc(Br)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
ABL1 P00519 2/20 0.50
SRC P12931 2/20 0.50
HPN P05981 1/20 0.47
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
NOD2 Q9HC29 1/20 0.46
NOD1 Q9Y239 1/20 0.46
PTGER3 P43115 1/20 0.44
POLB P06746 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43
CSNK2A2 P19784 1/20 0.43
CSNK2A1 P68400 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6446020 0.92 KMT2A (0.48) MAPTNPC1RAB9ASMN1; SMN2ABL1
SCHEMBL6447140 0.89 PTGER3 (0.45) MAPTNPC1RAB9ASMN1; SMN2PTGER3
SCHEMBL6451555 0.89 CSNK2A2 (0.55) NPC1RAB9ASMN1; SMN2ABL1SRC
SCHEMBL6447131 0.88 ABL1 (0.46) MAPTNPC1RAB9ASMN1; SMN2ABL1
SCHEMBL6447202 0.88 KMT2A (0.46) MAPTNPC1RAB9ASMN1; SMN2ABL1
SCHEMBL6445418 0.88 MEN1 (0.51) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL6445978 0.87 SNCA (0.47) NPC1RAB9ASMN1; SMN2LMNAPTGER3
SCHEMBL6445716 0.87 GLB1 (0.49) MAPTNPC1RAB9ALMNAPTGER3
SCHEMBL6447053 0.86 CSNK2A2 (0.49) MAPTNPC1RAB9ASMN1; SMN2ABL1
SCHEMBL6448931 0.86 PTGER3 (0.46) MAPTNPC1RAB9ASMN1; SMN2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US claimed
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 MAPT 3346/4885NPC1 1404/4885RAB9A 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.